Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04120493` - Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease	Phase 1/Phase 2
Completed	`NCT02956148` - Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers	Early Phase 1
Terminated	`NCT02494778` - A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease	Phase 2
Completed	`NCT02208934` - Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers	Phase 1
Completed	`NCT02216474` - Brain Stimulation in Movement Disorders	N/A
Completed	`NCT02197130` - Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease	Phase 2
Completed	`NCT01502046` - Neuroprotection by Cannabinoids in Huntington's Disease	Phase 2
Terminated	`NCT00712426` - Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Phase 3
Completed	`NCT00670709` - Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Completed	`NCT00029874` - Minocycline in Patients With Huntington's Disease	Phase 1/Phase 2
Terminated	`NCT02231580` - Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients	Phase 2
Completed	`NCT02215616` - A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod	Phase 2
Not yet recruiting	`NCT02551705` - Functional Imaging of Social Cognition in Premanifest Huntington's Disease	N/A
Active, not recruiting	`NCT02101957` - Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)	Phase 2/Phase 3
Completed	`NCT00990613` - A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin	Phase 1
Completed	`NCT01521832` - Escalating Dose Study in Healthy Volunteers With SEN0014196	Phase 1
Completed	`NCT00975481` - A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users	Phase 1
Completed	`NCT00387270` - Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT00095355` - Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease	Phase 2
Completed	`NCT00026988` - Creatine Therapy for Huntington's Disease	Phase 1/Phase 2

NCT number	NCT01806896
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2
Start date	September 2013
Completion date	January 2015

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms